Last week, GPCR biotech Septerna (SEPN) plummeted 47% after halting its lead candidate’s Phase 1 trial, just four months after the IPO. It’s far from the only recent biotech IPO to trade down substantially....read more
Updated Monday, 2/24.While the calendar looks quiet for the week ahead, some small deals may join late.Singapore healthcare practice Basel Medical (BMGL) is tentatively scheduled to raise $10 million at an $83 million market cap. Through its two medical...read more
Updated Monday, 2/3.Three IPOs are currently scheduled for the week ahead, and a few more sizable names are eligible to launch.Titan America (TTAM), the US business unit of Titan Cement, plans to raise $396 million at a $3.0 billion market cap. Operating...read more
US IPO Week Ahead: Small IPOs may list amid market volatility
...read more
Biotech bust: 2024 biotech IPOs average a -52% return
Last week, GPCR biotech Septerna (SEPN) plummeted 47% after halting its lead candidate’s Phase 1 trial, just four months after the IPO. It’s far from the only recent biotech IPO to trade down substantially....read more
US IPO Week Ahead: IPO market set to end February on a quiet note
Updated Monday, 2/24.While the calendar looks quiet for the week ahead, some small deals may join late.Singapore healthcare practice Basel Medical (BMGL) is tentatively scheduled to raise $10 million at an $83 million market cap. Through its two medical...read more
US IPO Week Ahead: Cement carve-out leads the IPO calendar as more gear up to launch
Updated Monday, 2/3.Three IPOs are currently scheduled for the week ahead, and a few more sizable names are eligible to launch.Titan America (TTAM), the US business unit of Titan Cement, plans to raise $396 million at a $3.0 billion market cap. Operating...read more